UPDATED: Monday, July 14 at 9:35 a.m. ET A GSK label expansion bid for respiratory syncytial virus vaccine Arexvy is under review at the FDA.

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

AS01-adjuvanted RSV and shingles vaccines were tied to a lower dementia risk in older adults. Compared with flu vaccine recipients, those who had the AS01 RSV shot had 29% more dementia-free time ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

The U.S. Food and Drug Administration has approved GSK's prefilled syringe presentation of Shingrix (zoster vaccine ...